MLYS
NASDAQ HealthcareMineralys Therapeutics, Inc. - Common Stock
Biotechnology
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
๐ Market Data
| Price | $26.05 |
|---|---|
| Volume | 761,200 |
| Market Cap | 2.30B |
| Beta | 0.680 |
| RSI (14-Day) | 41.7 |
| 200-Day MA | $30.67 |
| 50-Day MA | $26.43 |
| 52-Week High | $47.65 |
| 52-Week Low | $14.26 |
| Forward P/E | -10.42 |
| Price / Book | 3.37 |
๐ฏ Investment Strategy Scores
MLYS scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (88/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Over-Hyped (23/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find MLYS in your text
Paste any article, transcript, or post โ the tool will extract MLYS and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-08-17.